Hyderabad: Dr Reddy’s Laboratories Ltd on Thursday announced that it has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Ltd to commercialise Vonoprazan tablets in India. The pharma major will market Vonoprazan tablets under its trademark VONO. It will be available in two strengths, 10mg and 20mg.

Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders. MV Ramana, CEO, Branded Markets-India, Dr Reddy’s, said: “For over three decades, patients and healthcare professionals have trusted our products in the gastrointestinal segment including well-known brands such as Omez, Razo and others.